DNA — Ginkgo Bioworks Holdings Income Statement
0.000.00%
Last trade - 00:00
- $1.86bn
- $917.53m
- $251.46m
- 41
- 17
- 31
- 20
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 54.2 | 76.7 | 314 | 478 | 251 |
Cost of Revenue | |||||
Gross Profit | 54.2 | 61 | 184 | 273 | 197 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 126 | 214 | 2,142 | 2,655 | 1,158 |
Operating Profit | -71.6 | -137 | -1,828 | -2,177 | -907 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -120 | -125 | -1,838 | -2,121 | -893 |
Provision for Income Taxes | |||||
Net Income After Taxes | -120 | -127 | -1,837 | -2,106 | -893 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -119 | -127 | -1,830 | -2,105 | -893 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -119 | -127 | -1,830 | -2,105 | -893 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.064 | -0.068 | -1.35 | -1.25 | -0.349 |